Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16186792
Wu D, et al. (2006) ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene 25, 1153-64 16186792
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T203-p - ERK1 (mouse)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MEK1 (mouse) pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, transfection of dominant-negative enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea increase
U0126 hydroxyurea inhibit treatment-induced increase

Y205-p - ERK1 (mouse)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MEK1 (mouse) pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, transfection of dominant-negative enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea increase
U0126 hydroxyurea inhibit treatment-induced increase

S139-p - H2AX (mouse)
Modsite: GKKASQAsQEY____ SwissProt Entrez-Gene
Orthologous residues
H2AX (human): S139‑p, H2AX (mouse): S139‑p, H2AX (rat): S139‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea increase
U0126 hydroxyurea inhibit treatment-induced increase

S18-p - p53 (mouse)
Modsite: ISLELPLsQETFSGL SwissProt Entrez-Gene
Orthologous residues
p53 (human): S15‑p, p53 iso2 (human): S15‑p, p53 iso4 (human): , p53 (mouse): S18‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (green monkey): S15‑p
Characterization
Methods used to characterize site in vivo peptide sequencing, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hydroxyurea increase
U0126 hydroxyurea inhibit treatment-induced increase